干细胞移植治疗血栓闭塞性脉管炎的进展  

Advances in stem cell transplantation for thromboangiitis obliterans

作　　者：杨金江 杨镛[1,2] 马振桓 YANG Jinjiang;YANG Yong;MA Zhenhuan(Department of Vascular Surgery,the Fourth Affiliated Hospital of Kunming Medical University,Kunming,Yunnan 650000,P.R.China;Vascular Surgery Center of Yunnan Province,Kunming,Yunnan 650000,P.R.China)

机构地区：[1]昆明医科大学第四附属医院血管外科,昆明650000 [2]云南省血管外科中心,昆明650000

出　　处：《华西医学》2020年第3期357-362,共6页West China Medical Journal

基　　金：云南省卫生科技计划项目(2017NS137)。

摘　　要：干细胞移植是治疗血栓闭塞性脉管炎的主要方法之一。近年来,干细胞移植在治疗机制方面的研究有所进展,一批专门针对血栓闭塞性脉管炎的干细胞临床试验结果相继发表,部分新的干细胞种类逐渐运用于临床,适应证的把控和移植方法逐渐成熟,其安全性并无太大争议。此外,有研究表明干细胞移植的疗效受到多方面影响,部分因子对移植后截肢的可能性有一定的预测作用。该文就干细胞移植治疗血栓闭塞性脉管炎的临床研究进展进行综述,旨在为干细胞移植更好地用于治疗血栓闭塞性脉管炎提供一定依据。Stem cell transplantation is one of the main methods to treat thromboangiitis obliterans(TAO). In recent years, research on the treatment mechanism of stem cell transplantation has made some progress. The results of a number of stem cell clinical trials specifically for TAO have been published. Some new stem cell types have gradually been used in the clinic. There is no major dispute over security. In addition, research shows that the efficacy of stem cell transplantation is affected in many ways, and some factors have a certain predictive effect on the possibility of amputation after transplantation. This paper reviews the clinical research progress of stem cell transplantation for TAO, and aims to provide some basis for the better use of stem cell transplantation in the treatment of TAO.

关 键 词：干细胞移植 血栓闭塞性脉管炎 临床研究 疗效评估 严重不良事件 

分 类 号：R543[医药卫生—心血管疾病] R457.7[医药卫生—内科学]